Showing posts with label generic drugs. Show all posts
Showing posts with label generic drugs. Show all posts

Sunday, October 14, 2012

Restriction to Three Colors - Black, Yellow and Red

(c) 2000 The Animating Apothecary

(c) 2000 The Animating Apothecary

An experiment in limitations, using density and shading and three total colors.
It's a way to empathize with photographers dealing with two-strip Technicolor in the 1930s.

Monday, May 21, 2012

A Rather Disturbing Trend in 'Medicine'

A recent link from "Physician's Money Digest" is as follows.   I find it at least disturbing that the article celebrates the profits that can be had in treating cancer, and how it can offer the information to physicians who might be willing to benefit from judicial investments.  I contend that a logical sequel to this would be a listing of the 10 Most Profitable Mortuary Chains.
Here's the article:
 
10 Best-Selling Cancer Drugs
Right now oncology is the main attraction, which makes sense considering ASCO is just two weeks away. But oncology drugs have always garnered a lot of attention because the diseases they treat are so scary for the patients, plus they can be quite costly. (italics mine)

But the good thing (for the pharmaceutical companies) is that these drugs aren’t facing generic competition like some other drugs have to. As a result, expensive and older treatments are contending with low-cost generics for sales, meaning they’re still bringing in a pretty penny for the company
. (emphasis mine - again, what are we celebrating here?  More effective treatments?  Or more expensive - and thus, profitable - treatments for drug companies?  And are any of these treatments more effective, or just more profitable?  And isn't it just about the creepiest thing to consider success not by outcomes, or benefits to the patients, but as profit from sales of these drugs.... what a world, what a world... )

FiercePharma released a list of the top 10 best-selling cancer drugs based on how much they brought in U.S. sales over the last year. (My interruption again:  they also have a nice discussion on whether drug company CEOs get paid enough!!! So far their newsletter is free, so go there and get the daily scoop on what PharmaLand is doing behind the curtain)....
(And look how the information is presented, like it's some Top Ten on the David Letterman Show)
10. Tarceva
Company:
Genentech
2011 sales:
$564.2 million
FDA approvals:
Non-small cell lung cancer, 2004; pancreatic cancer, 2005; NSCLC maintenance therapy, 2010.

9. Xeloda

Company:
Genentech
2011 sales:
$647.6 million
FDA approvals:
Metastatic colorectal cancer, 1998; metastatic breast cancer, 2002; adjuvant colon cancer therapy, 2005.

8. Velcade

Company:
Millennium Pharmaceuticals, a unit of Takeda Pharmaceutical Industries, in partnership with Johnson & Johnson
2011 sales:
$692.7 million
FDA approvals:
Multiple myeloma, 2003; mantle cell lymphoma, 2006; first-line multiple myeloma, 2008.

7. Erbitux

Company:
Eli Lilly, in partnership with Bristol-Myers Squibb
2011 sales:
$703.3 million
FDA approvals:
EGFR-positive colorectal cancer, 2004; second line in head and neck cancer, 2006; first line in recurrent or metastatic head and neck cancer, 2011.

6. Alimta

Company:
Eli Lilly
2011 sales:
$1.04 billion
FDA approvals:
Malignant pleural mesothelioma, 2004; non-small cell lung cancer, 2008; NSCLC maintenance therapy, 2009.

5. Eloxatin

Company:
Sanofi
2011 sales:
$1.2 billion
FDA approvals:
Colorectal cancer, 2002; adjuvant use in colorectal cancer, 2004; new formulation, 2005.

4. Gleevec

Company:
Novartis
2011 sales:
$1.51 billion
FDA approvals:
Chronic myelogenous leukemia, 2011; gastrointestinal stromal tumors, 2002; Philadelphia-chromosome positive acute lymphocytic leukemia, 2006; dermatofibrosarcoma protuberans, 2006; certain myelodysplastic/myeloproliferative diseases, 2006; hypereosinophilic syndrome/chronic eosinophilic leukemia, 2006; aggressive systemic mastocytosis, 2006; adjuvant GIST treatment, 2012.

3. Herceptin

Company:
Genentech
2011 sales:
$1.66 billion
FDA approvals:
Metastatic HER2-positive breast cancer, 1998; adjuvant in early-stage HER2-positive breast cancer, 2006; additional adjuvant approvals, 2008; HER2-positive gastric or gastroesophageal junction cancer.

2. Avastin

Company:
Genentech
2011 sales:
$2.66 billion
FDA approvals:
Metastatic colorectal cancer, 2004; non-small cell lung cancer, 2006; breast cancer, 2008 (revoked in 2011); kidney cancer, 2009; brain cancer, 2009.
AND HERE'S NUMBER ONE - The drumroll, please!!!!
1. Rituxan
Company: Genentech
2011 sales:
$3 billion
FDA approvals:
Non-Hodgkin lymphoma, 1997; rheumatoid arthritis symptoms, 2006; rheumatoid arthritis disease progression, 2008; chronic lymphocytic leukemia, 2010; Wegener's granulomatosis and microscopic polyangiitis, 2011.

Ka- CHING!!!!!!

Tuesday, December 06, 2011

And so Albion and Marshall Don't Feel Left Out

Albion – Population 14224 (2010)

                         Stimulants  Vicodin like    Oxy-like    Methadone
totals               127774          737092           73520          134644
Per Capita         8.98              51.82              5.17               9.47



Marshall - population 14646 (2010)

totals               97505           375008             37238         69785
Per Capita       6.66               25.60                2.54              4.76

Monday, December 05, 2011

Battle Creek - You've Got A Problem!

The Michigan Automatic Prescription Service (MAPS) offers up a lot of information on controlled substance usage as reported from the state's pharmacies.  Their website even provides the raw data for the entire year of 2010, broken down by zip code.
After some research, it was possible to track down the populations for those zip code regions, then break the general use down 'per capita.'
The categories chosen for this snapshot of 2010 were 'stimulants' (meaning, all varieties of Ritalin, Adderall, Concerta, and its chemical relatives), 'hydrocodone' (for all drugs similar to Vicodin), 'oxycodone' (for those like Oxycontin), and 'methadone.'
The 49014 area corresponds to an area near Battle Creek known as "Harper Creek."  The 49015 refers to the "Lakeview" region, with 49016 being those who use a PO box as their primary address, 49017 referring to the city's northern side, and 49037 to the general region known as "Urbandale."
I recommend checking out the MAPS program and looking up your particular region and crafting a similar spreadsheet.  Battle Creek may look to be problematic, but I'm almost thinking that other regions may have a bigger problem....
Now, contemplate the causes.....

Monday, September 26, 2011

A Bit of Pharmacy History - 1919

A couple of drug pages from the E. R. Squibb and Son's "Materia Medica" book of fine, pure products from 1919.  At this point, the FDA had been in place 13 years....


...I am pretty certain that by 1919, these products required a prescription...
The text on cannabis reads:

"Cannabis has been employed as a Sedative, Anodyne and Hypnotic, in cases where opium does not agree with the patient. Unlike the latter, it causes neither nausea nor constipation. It produces at first a mental stimulation, which is later followed by a calmer mood and finally by sleep. It is used in acute and chronic mental derangements, in neuralgia, migraine, gout and rheumatism. In combination with the bromides (see Tab­lets Triple Bromides and Cannabis Compound) it is employed in hysteria, delirium tremens and mild cases of mania. All patients do not respond to it alike; and while no doubt idiosyn­crasy plays a great part, yet the quality of the drug has much to do with its constitutional effect. In all our preparations of this drug the best quality of hemp is used. "

Wednesday, September 21, 2011

A Moment of Snarkiness from the 2010 Edition...


 Because sometimes you can smell people before you see them.....


(c) MMIX The Animating Apothecary



        (well so much for making an animated GIF out of this one!)  

Saturday, September 03, 2011

1993 - Pre HIPAA and Mandated PharmD Degrees....

Here's a pilot that never got airborne, from 1993.  After about 5 months of meetings, a complete pharmacist recast, and three days of shooting video at pharmacies and laudromats that are no longer in business, I assembled this linear editing exercise with a pair of S-VHS players and lots of tachyarrhythmia.  And coffee...did I need to mention coffee?

Needless to say, the 10-episode series never went beyond these 6 minutes, and nobody gets to come around the pharmacy counter anymore without a supoena.  The "even longer for a clinical degree" - the PharmD - is now the only bona-fide entry card to "Behind the Counter" these days.

Snagged this to digital just before the original from 1993 began crumbling.  Lots of color shifts and sound drops..... egad....